Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report
2011

Case of a Newborn with Down Syndrome and Myeloproliferative Disorder

Sample size: 1 publication Evidence: low

Author Information

Author(s): Tragiannidis Athanasios, Pana Zoe Dorothea, Papageorgiou Theodotis, Hatzipantelis Emmanuel, Hatzistilianou Maria, Athanassiadou Fani

Primary Institution: Second Pediatric Department, Aristotle University of Thessaloniki, Ahepa General Hospital, Thessaloniki, Greece

Conclusion

This case highlights that tumor lysis syndrome can occur in newborns with transient myeloproliferative disorder and Down syndrome, and it can be effectively treated with rasburicase.

Supporting Evidence

  • The patient developed tumor lysis syndrome as a complication of transient myeloproliferative disorder.
  • Rasburicase was used successfully to treat the tumor lysis syndrome.
  • This is the first reported case of a newborn with Down syndrome and transient myeloproliferative disorder treated with rasburicase.

Takeaway

A baby with Down syndrome had a blood condition that caused too many white blood cells, leading to a serious problem called tumor lysis syndrome, but doctors helped her get better with medicine.

Methodology

The patient was treated with cytosine-arabinoside and rasburicase due to hyperleukocytosis and the risk of tumor lysis syndrome.

Participant Demographics

A seven-day-old Caucasian baby girl with Down syndrome.

Digital Object Identifier (DOI)

10.1186/1752-1947-5-407

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication